Company: LNAI
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001731122-25-000067
Chunk: 0

Company: Lunai Bioworks Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of New Chief Financial Officer

Effective January 6, 2025, the board of directors (the “ Board”)
of Renovaro Inc. (the “ Company” or “ Renovaro”) appointed Nathen Fuentes, age 42, as Chief Financial
Officer of the Company. Mr. Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth
and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial leadership roles.
Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor
relations, human resources, finance, accounting, and revenue cycle functions. Prior to joining Renovaro he served as Chief Financial Officer
at Telomir Pharmaceuticals (September 2023 to June 2024), an emerging leader in age-reversal science. Previously, Mr. Fuentes worked for
mid-market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of Emergence
Health Holdings (May 2023 to September 2023), Divergent Dental Group (July 2022 to May 2023), Family First Homecare (2019 to July 2022)
and Dermatology Medical Partners (2017 to 2019). He also served as the Controller of Glytec (2013 to 2017), as an Experienced Associate
at PricewaterhouseCoopers (2012 - 2013), and held various managerial positions with homebuilding companies prior to his experience with
PricewaterhouseCoopers. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science
in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.

In connection with his appointment,
the Company entered into an employment agreement (the “ Employment Agreement”) which provides that Mr. Fuentes’
base salary will be $280,000 per year, and he will be eligible to receive a performance bonus of up to $40,000 per year, which will be
payable on or before March 15thof each calendar year. For calendar year 2025, Mr. Fuentes will be eligible for a pro-rated
performance bonus. The Employment Agreement also provides for an equity incentive grant of 250,000 stock options,